Cost major barrier to NIPT use, say physicians
Changes to practice guidelines and insurance coverage are needed, the authors say.
Results of a survey published in the September issue of The Journal of Maternal-Fetal & Neonatal Medicine reveal that insurance coverage is considered the biggest barrier to routine use of noninvasive prenatal testing (NIPT).
Researchers designed a questionnaire to assess ob/gyns’ knowledge of and attitudes toward screening options for aneuploidy, with a focus on NIPT. Questions evaluated current practices regarding aneuploidy screening as well as the physicians’ opinions of and experiences with NIPT.
The respondents identified NIPT as clinically superior to traditional screening methods and indicated that they would like ACOG to formally recommend NIPT for any pregnant woman. Of note, nearly 15% misunderstood NIPT as being a diagnostic test for fetal aneuploidy.
More than 81% of the respondents said they would use NIPT as a first-line screening test if patients' insurance offered full coverage.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
